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ABSTRACT
Novel approaches for classification, including molecular features, are needed to 
direct therapy for men with low-grade prostate cancer (PCa), especially men on active 
surveillance. Risk alleles identified from genome-wide association studies (GWAS) 
could improve prognostication. Those risk alleles that coincided with genes and 
somatic copy number aberrations associated with progression of PCa were selected 
as the most relevant for prognostication.
In a systematic literature review, a total of 698 studies were collated. Fifty-
three unique SNPs residing in 29 genomic regions, including 8q24, 10q11 and 19q13, 
were associated with PCa progression. Functional studies implicated 21 of these 
single nucleotide polymorphisms (SNPs) as modulating the expression of genes in 
the androgen receptor pathway and several other oncogenes. In particular, 8q24, 
encompassing MYC, harbours a high density of SNPs conferring unfavourable 
pathological characteristics in low-grade PCa, while a copy number gain of MYC in 
low-grade PCa was associated with prostate-specific antigen recurrence after radical 
prostatectomy.
By combining GWAS data with gene expression and structural rearrangements, 
risk alleles were identified that could provide a new basis for developing a 
prognostication tool to guide therapy for men with early prostate cancer.
INTRODUCTION
Prostate cancer (PCa) is the most common cancer 
in men [1], with around 160,000 new cases each year in 
the USA alone [2]. Severity is conventionally assessed 
using Gleason score, prostate specific antigen (PSA) levels 
and tumour volume [3]. Approximately 80% of men in 
the US with PCa are diagnosed with stage I localised 
disease many of whom also have a low to intermediate 
risk of progression [4]. Men who present with low-risk 
PCa as defined by a Gleason score of 6 (3+3) and whose 
life expectancy is thought to be at least 10 years, are 
usually managed through active surveillance (AS) [5, 6]. 
AS aims to reduce over-treatment through monitoring 
the disease, with the requirement for radical intervention 
assessed with regular PSA-tests and biopsies rather than 
intervening at diagnosis [7]. The patient on AS can then 
be redirected to curative treatment in the event of short 
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PSA doubling time [8], deteriorating histopathological 
factors on repeat biopsies or other factors, such as anxiety 
from living with an untreated cancer. Approximately 33% 
of men with low-grade tumours managed on AS upgrade 
to a higher Gleason score within 5 years [9]. At present, 
there are no means of identifying which patient will 
progress; therefore, there is an urgent need to improve risk 
stratification. Molecular markers may help to discriminate 
indolent and aggressive clinical phenotypes, and inform 
patient stratification for men with low-risk PCa on AS.
Gene expression-based companion diagnostics 
for low-grade PCas
Gene expression profiling of PCa may help to 
stratify patients into high and low risk for disease 
progression [10]. Three commercially available tests, 
namely Prolaris® by Myriad Genetics (Salt Lake City, 
UT, USA) [11], Oncotype DX®, by Genomic Health 
(Redwood City, CA, USA) [12] and Decipher Biopsy™ 
by GenomeDx Biosciences (San Diego, CA, USA) [13, 
14] are primarily focused on measuring the expression 
levels of genes involved in proliferation [14]. As in many 
cancers, expression of such genes can be used as a proxy 
indication of aggressive tumour cells [15].
Germline single nucleotide polymorphisms as 
risk factors
A further potential, non-invasive, avenue of 
identifying progression in men with low-grade PCa, could 
be the investigation of susceptibility single nucleotide 
polymorphisms (SNPs), obtained from a simple blood test. 
Several genome-wide association studies (GWAS) have 
reported positive family histories [16] with an associated 
2-to 4-fold increased risk of developing PCa [17]. The 
Stockholm 3 Model (STHLM3) can predict if a patient has 
a Gleason score ≥7 [18] and has been shown to have an 
increased sensitivity of 20% over current clinical markers 
in a Swedish population [19].
The PCa genome
Even in localised, non-indolent PCa, a striking inter-
tumoural heterogeneity exists at the molecular level [20], 
including tumours with complex structural rearrangements 
such chromothripsis and chromoplexy [21]. The PCa 
genome is thought to evolve in abrupt, periodic bursts, 
resulting in complex, large-scale reshuffling of the 
genome, known as punctuated evolution. Most of these 
complex rearrangements are thought to occur as early 
events [21]. It follows that genomic alterations present in 
localised low-grade PCa may provide indicators of future 
progression, perhaps increasing the functional effects of 
germline SNPs which could be regarded as “hard-coded” 
markers for the stratification of men on AS with low-risk 
PCas [21, 22].
These “hard-coded” markers could help circumvent 
the principal challenge of molecularly characterising 
PCa – multiple, heterogeneous tumour foci. Biopsies have 
a 23–46% likelihood of sampling errors with an increased 
chance of missing a higher grade or higher-stage tumour 
[23]. If a higher-grade carcinoma is detected through 
repeat biopsies in a man on AS, it is unknown whether 
this is the biological progression of the original low-grade 
PCa or a pre-existing clone which has been missed in the 
initial biopsy. 
Here, we systematically collected diverse molecular 
data associated with aggressiveness and progression of 
PCa to highlight potential risk alleles. Due to the paucity 
of published low-grade GWAS studies, high-grade PCa 
GWAS studies were also included. We initially assessed 
germline SNPs with known associations for disease 
progression and aggressiveness in PCa, to identify 
potential genomic loci. Since somatic aberrations can 
influence germline changes, and vice versa [24], we 
then integrated available data on the functional roles of 
these SNPs, as well as copy number and gene expression 
studies to assess the potential relevance of these loci for 
the aggressive progression of low-grade PCa.
RESULTS
A total of 22 PCa GWAS, and GWAS validation 
studies across different populations were used to identify 
SNPs potentially associated with aggressiveness, 
progression, biochemical recurrence, and metastasis. Five 
of the 22 studies focused on both identifying novel risk 
variants and validating previous findings (>1,500 SNPs) 
[16, 25–28]. Two studies were GWAS meta-analyses [29, 
30], and 17 studies primarily sought to validate previously 
identified SNPs (<100 SNPs) [31–45].
Fifty-three unique SNPs were determined from 
these studies, residing in 29 unique loci across the 
genome (Supplementary Table 1). Nine of these SNPs 
were significantly associated with aggressive disease or 
unfavorable characteristics in several population studies, 
e.g. rs10993994 [16, 44, 36, 40, 41] was significantly 
associated with aggressiveness in Asian Indian, 
Ashkenazi, Taiwanese, European, African American, 
Australian, Canadian and US populations (Supplementary 
Table 1). Three SNPs were reported in three or more 
studies (Supplementary Table 1), rs10993994, rs1447295, 
and rs2735839. All three SNPs were at cytobands with 
other SNPs also found to be associated with aggressive 
PCa: rs10993994 at 10q11.23 harbouring rs7920517, 
rs1447295 at 8q24.21 located along with seven other 
SNPs, and rs2735839 located along with three other 
SNPs (Supplementary Table 1) No SNPs in high linkage 
disequilibrium with rs2735839 were found to be associated 
with PCa [46].
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A total of three low-grade and low-volume-tumour 
studies [5, 37, 43] were initially selected from the search 
criteria. Only two of these were finally selected through 
the inclusion criteria [37, 43] (Supplementary Figure 1). 
The first study was carried out on radical prostatectomies 
of AS patients where unfavourable pathological 
characteristics were measured [37] and corroborated a risk 
allele rs1447295, which was also found to be associated 
with aggressive PCa by three other studies [45, 44, 41]. 
The second study involved a comparison between men 
who upgraded from Gleason 6 with those who remained 
stable [43]. Together, these studies, reported 5 SNPs, 
where 2 were found in the same loci as SNPs identified 
in more aggressive studies, rs1447295 on 8q24 and 
rs11228565 on 11q13.3. The third low-grade study by Goh 
et al, [5] conducted a prospective study of 412 men on 
AS where 56 patients histologically upgraded upon repeat 
biopsies. All 39 SNPs, including rs1447295, 10993994, 
and rs2735839, analysed in this study failed to be 
significantly associated with upgrading and thus the study 
was excluded (Supplementary Figure 1). Other studies 
similarly failed to find a significant association between 
these SNPs and aggressive PCa [47]. Study design or 
sample size may play a factor in this as these SNPs have 
well documented functional effects on tumourigenesis in 
PCa [48–50].
Functional involvement of germline SNPs in 
disease progression
Post-GWAS functional studies aim to show that 
SNPs affect particular genes that may have a direct role 
in disease progression. Among the identified SNPs, 24 
were located in intergenic regions, while 29 resided in 
either long noncoding RNAs or protein coding genes. 
Rs7652331 and rs1058205 were located in exons of genes 
(Table 1). Functional studies conducted on 21 (Table 1) 
of these 53 SNPs (Supplementary Table 1) were used to 
provide further evidence of their role in PCa progression. 
These 21 SNPs may drive aggressive PCa by acting 
through the oncogene MYC, the androgen receptor (AR) 
pathway, or through modulating known PCa biomarkers 
such as MSMB or KLK3, and genes involved in invasion, 
proliferation, suppression or metastasis.
MYC pathway
Of the three SNPs reported in three or more studies 
in this review (rs1447295, rs10993994, and rs2735839), 
rs1447295 was found to be significantly associated with 
unfavourable outcomes in men with Gleason 6 (3+3), PSA 
recurrence [44] and aggressive PCa [45, 51, 41] (Table 1). 
This SNP is located within noncoding RNA LOC727677 
and next to POU5F1B, which in turn has the oncogene 
MYC as its neighbouring gene [48]. Cai et al, 2016 [50] 
showed that rs1447295, as well as other PCa risk alleles on 
8q24, interfere with both MYC and POU5F1B’s activities, 
through cell proliferation studies in LNCaP and C4-2B 
PCa cell lines. MYC is an established oncogene [33, 52], 
while POU5F1B has been shown to play an important role 
in PCa progression [50]. POU5F1B is expressed in normal 
prostate tissue and is overexpressed in prostatic carcinoma, 
compared to normal prostatic tissue surrounding 
the carcinoma [49]. Furthermore, PCa cell lines that 
ectopically overexpress POU5F1B form fewer cell-cell 
junctions and exhibit significantly increased invasiveness 
in vitro [49]. Given the evidence of rs1447295 functionally 
altering expression of MYC and POU5F1B [50], its 
influence on prostate tumor progression and metastasis 
can be asserted. Adding to the involvement of risk alleles 
on MYC, our analysis also highlighted rs6983267, which 
has been shown in colorectal cancer to interact with MYC 
[48] and rs4242382, affecting the expression of MYC and 
POU5F1B [50].
Androgen receptor pathway
There is evidence supporting a role for 4 SNPs 
in modulating the genes of the AR pathway. The first, 
rs17021918, shows an association with BMPR1B via 
eQTL, a gene regulated by AR [53]. The second risk 
allele implicated in this pathway is rs10486567, which is 
located in an intron of JAZF1 found to affect both NKX3-1 
and FOXA-AR motifs in the JAZF1 gene. This risk allele 
results in a 39% increase in basal activity and a 28% fold-
increase in androgen stimulated enhancer activity [54] 
(Table 1). The third risk allele, rs7679673, was found 
to significantly reduce TET2 expression [55], which 
normally binds to the androgen receptor. This results in 
the capability of predicting disease progression and poor 
overall survival. Lastly, rs2939244 results in the variation 
of the androgen receptor-binding site gene ARRDC3 which 
affects prostate cancer specific mortality [56].
PCa biomarkers
Risk alleles that interact with other genes known 
to be PCa biomarkers were also identified. Rs10993994 
on 10q11 is proximal to the promoter region of MSMB, 
a urinary biomarker that outperforms urinary PSA [57] 
at differentiating men with prostate cancer at all Gleason 
grades. An association between rs10993994’s and levels of 
MSMB in prostate tissue was demonstrated, with levels of 
MSMB lowest in men homozygous for the high-risk allele 
(TT) and highest in men homozygous for CC [57].
Rs2735839 is located 600bp downstream of the 
PSA encoding KLK3 gene, and was found to modulate 
PSA levels [39]. The clinical relevance of this risk allele is 
supported by the observation that rs2735839 is associated 
with biopsy-proven aggressive PCa (Gleason ≥8) and 
could stratify Gleason 7 patients [39]. Three additional 
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Table 1: Functional information of 21 risk alleles identified to be associated with aggressive PCa
SNP Location Location of SNP – gene/Intergenic
Nearest coding gene/gene 
effected Potential SNP function
rs13385191 2p24.1 intron LDAH LDAH
down-regulates expression of LDAH – 
which is down-regulated in PCa and 
further reduced in metastatic prostate 
tumors versus primary prostate 
tumors [61]
rs2660753 3p12.1 Intergenic VGLL3/CHMP2B/POU1F1 SNP associated with the expression of VGLL3/CHMP2B/POU1F1 [58]
rs17021918 4q22 intron PDLIM5 BMPR1B
eQTL shows associated with (or 
fine mapped significantly with 
expression of) BMPR1B which is AR 
regulated [53]
rs7679673 4q24 Intergenic TET2
significantly reduced TET2 expression, 
a predictor of disease progression and 
poor overall survival as binds to the 
androgen receptor [42]
rs2939244 5q14.3 Intergenic ARRDC3/LUCAT1
variation in androgen receptor-binding 
site gene ARRDC3 affects prostate 
cancer specific mortality [56]
rs9364554 6q25.3 intron SLC22A3 SLC22A3
functional studies associate this 
risk allele with decreased SLC22A3 
transcript abundance [59]
rs10486567 7p15.2 intron JAZF1 JAZF1
affects both NKX3-1 and FOXA-AR 
motifs in JAZF1. SNP results in a 39% 
increase in basal activity and a 28% 
fold-increase in androgen stimulated 
enhancer activity [59]
rs6465657 7q21.3 intron LMTK2 LMTK2
effects LMTK2 expression between 
benign (n = 39) and malignant tissues (n 
= 21) (P = 0.002) [60]
rs6983267 8q24.21 intron LOC727677/CASC8 POU5F1B/MYC
long-range interaction with MYC in 
colorectal cancer [48]
rs1447295 8q24.21 intron CASC8/LOC727677 POU5F1B/MYC
interferes with both MYC and 
POU5F1B’s activities through cell 
proliferation studies in LNCaP and C4-
2B PCa cell lines [50]
rs4242382 8q24.21 intergenic POU5F1B/MYC implicated in the expression of MYC and POU5F1B [50]
rs1571801 9q33.2 intron DAP2IP DAB2IP
*decrease in DAB2IP expression induces 
metastatic prostate cancer in a tumour 
mouse model [67] and chemoresistance 
in human prostate cancer cell lines [68]
rs10993994 10q11.23 intron PARG/ TIMM23B MSMB associated with MSMB [57]
rs10896449 11q13.3 intergenic MYEOV/DUSP6 interacts with DUSP6 [62], which promotes invasion and proliferation [63]
(Continued )
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SNPs were identified in either the intron (rs62113212 and 
rs266870) or exon (rs2735839) of KLK3.
Tumourigenic genes
Nine risk alleles were found to modulate other 
tumourigenic genes. Genetic and functional analysis 
conducted by Grisanzio et al, [58] elucidated the 
functional relevance of both rs2660753 and rs9364554. 
Rs2660753 was found to be associated with the expression 
of VGLL3/CHMP2B/POU1F1. While rs9364554 was 
found to be associated with a decreased SLC22A3 
transcript abundance [58], and found to be down 
regulated in familial esophageal squamous cell carcinoma 
[59]. Other risk alleles have been shown to affect gene 
expression, such as rs6465657 on LMTK2 expression [60], 
a gene implicated in the development of prostate cancer 
[60]. Rs13385191, which is suggested to be a cis-acting 
expressed quantitative locus (eQTL) that down-regulates 
the expression of LDAH [61], a gene that is frequently 
down-regulated in PCa and is even further reduced 
in metastatic prostate tumors as compared to primary 
prostate tumors [61]. Rs10896449 likely interacts with 
DUSP6 [62], a gene that when knocked down promotes 
the invasion and proliferation of LNCap human prostate 
adenocarcinoma cells [63]. Rs11649743 potentially 
increases gene expression of HNF1B [64] and rs11568818, 
which is associated with increased MMP7 expression [65], 
a gene which mediates IL-17’s function in promoting 
prostate carcinogenesis in mice [66]. Two SNPs, reported 
as being significantly associated with aggressive PCa, 
reside in introns of genes, with their functional effect not 
yet determined, such as Rs1571801 located in the intron 
of DAP2IP. This gene is instrumental in tumourigenesis as 
it’s loss induces metastatic prostate cancer in an orthotopic 
mouse tumour model [67] and chemoresistance in human 
prostate cancer cell lines [68]. Rs9508016 is located 
within the intron of FLT1, a gene which has been shown 
to promote angiogenesis and metastasis [69].
Somatic copy number aberrations in PCa
Next, we hypothesised that the functional 
importance of these risk allele hotspots might be further 
elucidated if their somatic copy number aberrations 
(SCNAs) were altered in the genome. We evaluated the 
copy number data collected from different populations 
of low-grade and more aggressive PCa to see if this 
correlated with the SNPs we had identified. Seventeen 
of 53 SNPs were found in regions with SCNAs, such as 
a copy number gain on 8q24 encompassing rs1447295, 
rs10090154, rs6983267, rs4242382, rs16901966, 
rs6983561, rs6470517, and rs6999921 and gain on 11q13 
where rs10896449 and rs11228565 reside (Table 2).
Recurrent SCNAs indicative of aggression and 
metastases
Since PCa is predominately driven by DNA copy 
number loss and recurrent gains [70, 71], we hypothesise 
that SCNAs in low-grade PCa could be indicative for 
eventual metastasis or progression. SCNAs that predict 
PSA recurrence after radical prostatectomy include: a 
loss of PTEN [72], a simultaneous loss of PTEN, FAS 
SNP Location Location of SNP – gene/Intergenic
Nearest coding gene/gene 
effected Potential SNP function
rs11568818 11q22.2 intergenic MMP-7
associated with increased MMP7 
expression [65], which mediates IL-
17’s function in promoting prostate 
carcinogenesis in mice [66]
rs9508016 13q12.2 intron FLT1 FLT1
*increased FLT1 expression in prostate 
cancer [69]
rs11649743 17q12 intron HNF1B HNF1B potentially increases HNF1B gene expression [64]
rs62113212 19q13.33 intron KLK3 KLK3/KLK2 *gene encodes PSA
rs266870 19q13.33 intron LOC105372441 KLK3 *gene encodes PSA
rs1058205 19q13.33 exon KLK3 KLK3 *gene encodes PSA
rs2735839 19q13.33 intergenic KLK3 modulates PSA levels [39]
List of risk alleles associated with aggressive PCa, their respective chromosome, cytoband, and the location of each within 
either a gene or in an intergenic region as well as the gene they affect. Previously reported functional studies have been 
included to support these risk alleles in the role they play in aggressive PCa.
*not shown to directly affect gene expression.
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(10q23.31) and PAPSS2 (10q23.2–10q23.31) [73], a gain 
on 11q13.1 [74], a loss within 6q, a gain within 7q, a 
loss of 13q [75], a loss of 16q with or without a loss of 
PTEN [76], a gain of MYC [77], and a concurrent loss of 
8p22 and gain of 8q24 [70]. SCNAs in certain genomic 
locations increase in frequency with Gleason score. For 
example, a loss of 8p22 was detected in ~30% Gleason 
score 7 [78], 69% in high-grade clinically organ-confined 
PCa (Gleason >8) and increased to 100% in metastatic 
patients (Gleason score 10) [79–81].
SCNAs indicative of aggressiveness present in 
low-grade PCa
As the majority of SCNA studies have been 
conducted on high-grade PCa we sought to identify 
whether or not these were present and associated with 
an aggressive phenotype in low-grade PCa. A pooled 
low-grade PCa study found such SCNAs to be present, 
but at lower frequencies (>20%) than their higher-
grade counterparts. These included a loss within 6q 
(location of rs9364554), 8p, 10q23, 13q, and 18q and 
a gain within 8q [71]. Another low-grade SCNA study 
conducted by Fraser et al, [20] also observed these 
SCNAs at similar frequencies in ~25% of Gleason 6 PCa 
samples, suggesting that men with PCa displaying those 
aberrations may have an aggressive form of the disease, 
and that these events occur early on in the development 
of cancer providing further evidence of punctuated 
evolution.
Of the SCNAs associated with aggressive PCa 
in high-grade PCa, evidence of a gain within 8q, loss 
of PTEN and 8p were found to also be associated with 
an aggressive phenotype in low-grade PCa [78]. In this 
study, differences in PTEN loss, a gain of chromosome 
8q (encompassing MYC) and/or 8p loss (encompassing 
LPL on 8p22) were found in patients with only a Gleason 
pattern 3 versus those who had both Gleason pattern 3 and 
4. Similar SCNAs, such as a loss of 8p, were associated 
with high-grade PCa and biochemical recurrence after 
radical prostatectomy [82]. In addition, Trock et al, (2016) 
[78] discovered that a gain on MYC/8q was a feature of 
undersampling a higher Gleason score tumour and was 
shown to be predictive of systematic disease progression, 
earlier PCa-specific death and PSA recurrence after 
radical prostatectomy in other studies [82]. Moreover, 
this MYC/8q SCNA encompasses eight SNPs reported 
in this review (Supplementary Table 1). Furthermore, a 
loss of PTEN was not only significantly associated with 
undersampling (p=0.03, conditional logistic regression) 
by Trock et al, (2016) but was also predictive of PSA 
recurrence after radical prostatectomy [72].
Gene expression reflective of copy number 
aberrations
We next assessed whether genes from published 
gene signatures are encoded in genomic regions in which 
a) the identified germline SNPs reside; or b) SCNAs 
predictive of aggressive PCa were located. We collected 
Table 2: SNPs found in recurrent somatic copy number aberrations or within 5 gene signatures predicting PCa 
aggressiveness
Location SNP Somatic copy number aberration (SCNA) Gene from gene signature
3p rs2660753, rs7652331, rs1545985, gain 3p -
5q14.3 rs35148638, rs2939244 loss 5q -
6q25.3 rs9364554 loss 6q -
8p21.2 rs1512268 loss 8p22 -
8q24.21 rs6983267, rs1447295, rs4242382, rs10090154 gain 8q24 -
11q13.3 rs10896449, rs11228565 gain 11q13 TMEM132A [83]
13q12.2 rs9508016 loss 13q ZIC2, ZIC5 [87]
17q rs11649743, rs6504145, rs1859962 loss 17q -
19q13 rs11672691, rs62113212, rs266870, rs1058205, rs2735839, rs103294 -
KEAP1 [86], UPK1A [85], 
APOC1 [83]
20q13.33 rs2427345 - MYBL2, UBE2C [84]
Table containing a subset of genes from 5 gene signatures predicting PCa aggressiveness, Wu et al [84], Ross et al [86], 
Bibikova et al [88], and Sahabi et al [85]. The respective chromosome arm and when applicable, cytoband for each gene 
along with recurrent SCNAs associated with PCa [21] within the same locus. A subset of SNPs associated with aggressive 
PCa within the same locus are also shown.
Oncotarget12818www.impactjournals.com/oncotarget
data from five recently published PCa gene expression 
studies investigating progression, and recurrence along 
with the location of each gene (Table 2). These gene 
signatures were developed either from recurrent cohorts 
[83–85], by comparing high to low-grade PCas [86], or 
to predict upgrading upon repeat biopsies of Gleason 
6 cohorts [87]. From a total of 95 genes across all five 
signatures, only 2 genes ABCC11 and HOXC6 were 
found in common. ABCC11 expression was part of a gene 
signature predictive of recurrence [84] and between low 
to high grade PCas [86]. HOXC6, was found in both a 
signature indicative of recurrence [85] and a signature 
delineating low and high grade PCas [86]. Despite 
the limited number of overlapping genes between the 
signatures, we observed that the genomic position of 
risk alleles frequently coincides with genes from these 
signatures (Table 2). Ten of the 53 SNPs were in regions 
where the expression of genes was used in gene signatures 
of aggression. For example, CCNE2 located on 8q22 is 
upstream of three identified SNPs, and UPK1A and 
APOC1 reside on 19q13 where rs11672691, rs62113212, 
rs266870, rs1058205, rs2735839, rs103294, can be found 
(Table 2). In addition, several genes were found in regions 
of SCNAs that predict aggressive progression of PCa, 
such as TMEM132A on 11q12, which is next to a common 
SCNA on 11q13, and ZIC2, ZIC5, F10 are located on 13q, 
a frequently lost SCNA region.
DISCUSSION
This review collated GWAS studies that associated 
risk alleles with aggressive PCa, and included studies 
with patients who upgraded from Gleason 6 and patients 
with Gleason 6 and unfavourable histopathology. Twenty-
nine potential germline GWAS ‘hotspots’ indicative of 
aggressive disease progression were identified containing 
53 SNPs. These were then further assessed for their 
potential functional relevance. Of these, 17/53 were found 
in SCNAs associated with aggressive PCa and present to 
a lesser extent in low-grade PCa. Ten out of the 53 were 
found in gene expression signatures associated with PCa 
progression, further implicating the role these SNPs may 
have in aggressive tumourogenesis.
While SNPs are important for risk predictions in 
cancer, a singular SNP found to be associated to a disease 
through GWAS rarely has a sole effect on the disease. 
Most likely there is a complex mechanism underlying its 
effect. The use of functional studies conducted on 21 of 
the 53 risk alleles in combination with somatic genomic 
perturbations such as copy number status and gene 
expression levels provides further evidence that these 
regions play integral roles in the aggressive progression 
of PCa. Our work has implications in more than one 
population. Nine of the 53 identified SNPs identified were 
significantly associated with aggressive disease in more 
than one population.
We successfully identified SNPs within 29 loci. 
Rs1447295 was among 8 SNPs in the 8q24 hotspot and 
was found to be significantly associated with aggressive 
PCa in three studies [45, 44, 41], and adverse pathology 
in one low-grade GWAS study [37]. The effect of 
rs1447295 modulating MYC could be heightened by a 
gain or amplification at this locus, indicating the selective 
susceptibility of this hotspot to aggressive progression 
of the disease. Similar genomic hotspots of germline 
and somatic aberration alignments have been noted in 
breast cancer where tandem duplications were found to 
peak where two germline susceptibility loci were present 
on MYC [88]. Such regions are more prone to double 
stranded breaksand rely on faulty repair mechanisms that 
generate large tandem duplications [88]. We postulate that 
these hotspots and SCNAs, which are present in ~25% of 
patients with low-grade PCas [20], could be used to select 
patients whose disease might progress towards a more 
aggressive phenotype, deeming them worthy for further 
investigation in a clinical setting.
Limitations of this review include the GWAS and 
SCNA studies lack of consistent methodological reporting 
between studies examining low-grade PCa. Patients with 
a lower Gleason scoring PCa (<either Gleason score 6 or 
Gleason score 7) were compared to patients with more 
aggressive PCas in six case-case GWAS studies. However, 
only one study [42] in which the follow-up years of non-
aggressive PCa remaining indolent was available. Another 
limitation stems from uncertainty around the significance 
of gene expression signatures. Gene expression fluctuates 
rapidly, rendering these gene expression patterns plastic 
throughout the life of any cancer. Therefore, combining 
low-grade and aggressive PCa expression signatures has 
its weaknesses. Acknowledging the limitations inherent in 
the available data, cross-referencing the different domains 
of risk alleles, SCNA and gene expression might help to 
overcome such uncertainties and identify key features for 
disease progression in PCa.
More than one in five men eligible for AS will 
present evidence of more aggressive disease upon 
prostatectomy [89]. Conversely, some men who do not 
meet conventional AS criteria may in fact harbour indolent 
cancers that will not reduce their length or quality of 
life. Furthermore, the current AS monitoring paradigm 
relies heavily on invasive and costly re-biopsy, with 
its concomitant risks and side effects. As such, there is 
a powerful argument for further investigation into non-
invasive tests. In recent years, multiparametric MRI 
(mpMRI) has emerged as a potential non-invasive tool 
to detect clinical significant disease in men with low or 
intermediate risk of PCa [90]. Multi-platform non-invasive 
testing that integrates imaging and genomics, such as 
the 53 SNPs identified in this study with mpMRI, could 
conceivably present an effective method of determining 
candidacy for AS, and subsequent risk.
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MATERIALS AND METHODS
We focused on three specific types of data to predict 
PCa progression: germline GWAS risk alleles, SCNAs, 
and tumour gene expression data. Germline risk alleles of 
interest were identified. Manually curated functional risk 
alleles, SCNA and gene expression studies were used to 
investigate the potential relevance of these loci.
For GWAS data, we searched Embase and Pubmed 
using the following MeSH search terms: PCa, prostatic 
neoplasm, GWAS, genome-wide, inherited, aggressive, 
progression, active surveillance, death, and outcome 
for the period 2009-2017. We included GWAS studies, 
which either validated SNPs previously associated with 
PCa or compiled information regarding recurrence or 
progression of the disease. For each study, we assessed 
risk markers in their role of developing aggressive PCas, 
which may result in metastasis, biochemical recurrence, 
and death. Of 698 articles assessed, 24 were carried 
forward (Supplementary Figure 1) using the PRISMA 
statement [91].
To corroborate GWAS hotspots, research on 
SCNAs and gene expression profiles were identified 
in PubMed, until January 2017, using the search 
terms listed above as well as copy number and gene 
expression. We specifically included those studies with 
somatic copy number data derived from microarrays 
or DNA sequencing analysis, gene expression profiles 
from expression microarrays and RNA sequencing, 
and clinical information, including recurrence or 
progression of disease.
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